Clinical trials on other SGLT2 inhibitors, such as canagliflozin, dapagliflozin, and ertugliflozin, and their cardiovascular outcomes in T2D patients are still ongoing (6). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.